Suppr超能文献

单细胞转录组学分析基因编辑肾脏类器官中的肾病风险变异体。

Profiling Nephropathy Risk Variants in Genome-Edited Kidney Organoids with Single-Cell Transcriptomics.

机构信息

Division of Nephrology and Hypertension, Department of Medicine, Feinberg Cardiovascular and Renal Research Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Division of Nephrology, Department of Medicine, Kidney Research Institute, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington.

出版信息

Kidney360. 2020 Mar;1(3):203-215. doi: 10.34067/kid.0000422019.

Abstract

BACKGROUND

DNA variants in associate with kidney disease, but the pathophysiologic mechanisms remain incompletely understood. Model organisms lack the gene, limiting the degree to which disease states can be recapitulated. Here we present single-cell RNA sequencing (scRNA-seq) of genome-edited human kidney organoids as a platform for profiling effects of risk variants in diverse nephron cell types.

METHODS

We performed footprint-free CRISPR-Cas9 genome editing of human induced pluripotent stem cells (iPSCs) to knock in high-risk G1 variants at the native genomic locus. iPSCs were differentiated into kidney organoids, treated with vehicle, IFN-, or the combination of IFN- and tunicamycin, and analyzed with scRNA-seq to profile cell-specific changes in differential gene expression patterns, compared with isogenic G0 controls.

RESULTS

Both G0 and G1 iPSCs differentiated into kidney organoids containing nephron-like structures with glomerular epithelial cells, proximal tubules, distal tubules, and endothelial cells. Organoids expressed detectable only after exposure to IFN-. scRNA-seq revealed cell type-specific differences in G1 organoid response to induction. Additional stress of tunicamycin exposure led to increased glomerular epithelial cell dedifferentiation in G1 organoids.

CONCLUSIONS

Single-cell transcriptomic profiling of human genome-edited kidney organoids expressing risk variants provides a novel platform for studying the pathophysiology of APOL1-mediated kidney disease.

摘要

背景

与肾脏疾病相关的 DNA 变异,但病理生理机制仍不完全清楚。模式生物缺乏 基因,限制了疾病状态能够被再现的程度。在这里,我们提出了一种利用经过基因编辑的人类肾脏类器官进行单细胞 RNA 测序(scRNA-seq)的平台,用于分析不同肾单位细胞类型中 风险变异的影响。

方法

我们对人类诱导多能干细胞(iPSC)进行无足迹 CRISPR-Cas9 基因组编辑,将 高风险 G1 变异敲入到天然基因组位置。iPSC 分化为肾脏类器官,用载体、IFN-或 IFN-和衣霉素的组合处理,并进行 scRNA-seq 分析,以比较与同基因 G0 对照的差异基因表达模式的细胞特异性变化。

结果

G0 和 G1 iPSC 均分化为含有肾小球上皮细胞、近端肾小管、远端肾小管和内皮细胞等肾单位样结构的肾脏类器官。类器官仅在暴露于 IFN-后才表达可检测到的 。scRNA-seq 揭示了 G1 类器官对 诱导的细胞类型特异性反应差异。额外的衣霉素暴露应激导致 G1 类器官中肾小球上皮细胞去分化增加。

结论

表达 风险变异的人类基因组编辑肾脏类器官的单细胞转录组分析为研究 APOL1 介导的肾脏疾病的病理生理学提供了一个新的平台。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ffc/8809262/0947727ea226/KID.0000422019absf1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验